Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
Clover Health Investments, Corp. (CLOV) executive Jamie L. Reynoso, CEO, Medicare Advantage, reported a sale of 1,921 shares of Class A Common Stock on September 17, 2026 at $4.56 per share in an open-market or private transaction, leaving 2,803,446 shares held directly. The sale was effected under a Rule 10b5-1 trading plan adopted on March 12, 2026.
Clover Health Investments, Corp. (CLOV) reported that Joseph Frank Oldakowski, its VP of Finance and Controller, sold 3,170 shares of Class A Common Stock on September 16, 2026 at $4.64 per share. After this transaction, he held 275,897 shares directly.
The filing explains that these shares were sold to cover tax withholding obligations arising from the vesting of 6.25% of restricted stock units (RSUs) granted on June 16, 2025, under Clover Health’s equity incentive plans. The remaining RSUs vest quarterly in equal 6.25% installments through a final vesting date of June 16, 2029, subject to his continued service. The company states these are mandatory "sell to cover" transactions under its plan and do not represent discretionary trades. The filing also affirms the use of a Rule 10b5-1 trading plan for these sales.
Clover Health Investments, Corp. (CLOV) officer Jamie Reynoso filed a Rule 144 notice for a proposed sale of up to 1,921 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The shares to be sold were acquired on September 15, 2026 as Restricted Stock Units from the issuer.
Reynoso also reports several sales of Clover Health common stock in the prior three months, including transactions on July 6, July 8, July 15, July 17, and September 15, 2026, some of which were executed as 10b5-1 sales.
Clover Health Investments, Corp. (CLOV) reports that officer Joseph Frank Oldakowski has filed a notice to sell 3,170 shares of Class A Common Stock under Rule 144 through Morgan Stanley Smith Barney LLC on September 16, 2026. The shares relate to vested restricted stock units and will be sold in a "sell to cover" transaction to satisfy tax withholding obligations, which the filing states are not discretionary trades by Oldakowski.
In the prior three months, Oldakowski reported sales of 12,102 shares of Class A Common Stock for $58,815.72 on June 16, 2026 under a 10b5-1 plan and 20,000 shares for $103,200 on September 14, 2026.
Clover Health Investments, Corp. (CLOV) reports that officer Wai Conrad, CEO of Counterpart Health, filed a Form 4 disclosing the sale of 300,000 shares of Class A common stock on September 15, 2026. The sale was executed at a weighted average price of $4.72 per share under a Rule 10b5-1 trading plan adopted on June 8, 2026, with individual trade prices ranging from $4.60 to $5.06. The shares sold were held indirectly in a family trust for which he serves as co-trustee; after the sale, that trust held 1,170,056 shares, and he also reported 1,065,699 shares held directly.
Clover Health Investments, Corp. (CLOV) reported that its Chief Legal Officer Karen Soares sold 6,846 shares of Class A common stock on September 15, 2026 at a weighted average price of $4.78 per share in sales mandated to cover tax withholding on the final vesting of 6.25% of restricted stock units granted September 15, 2022. These transactions were effected as a required "sell to cover" under the company’s equity incentive plans and are not discretionary trades; following the sale, Soares directly holds 1,607,371 shares of Class A common stock.
Clover Health Investments, Corp. (CLOV) reported that Jamie L. Reynoso, CEO, Medicare Advantage, sold 9,273 shares of Class A Common Stock on September 15, 2026 at a weighted average price of $4.78 per share. The footnotes state these mandated "sell to cover" transactions were executed under the issuer’s equity incentive plans to satisfy tax withholding on the vesting of the final 6.25% of restricted stock units originally granted on September 16, 2022 and do not represent discretionary trades. Following the sale, Reynoso directly holds 2,805,367 shares of Class A Common Stock.
Clover Health Investments, Corp. (CLOV) received a Form 144 notice that officer Karen M. Soares may sell 6,416 shares of Class A common stock on September 15, 2026 through Morgan Stanley Smith Barney LLC.
The shares come from restricted stock units vesting as compensation, and the sales are described as a “sell to cover” transaction solely to satisfy tax withholding obligations, not as discretionary trades.
Clover Health Investments, Corp. (CLOV) received a notice that stockholder Jamie Reynoso intends to sell up to 8,691 shares of Class A common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $40,500.06 based on recent prices and with 435,441,337 shares of this class outstanding.
The shares relate to restricted stock units and the filing states the planned sale is a non‑discretionary “sell to cover” transaction to satisfy tax withholding obligations upon vesting and settlement, rather than a voluntary reduction in investment. The notice also lists prior 10b5‑1 plan sales by Reynoso over the past three months.
CLOVER HEALTH INVESTMENTS, CORP. (CLOV) received a notice that former officer Brady Priest intends to sell up to 215,291 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $999,574.58 as of September 15, 2026.
The notice also lists prior sales of CLOV common stock by Brady Priest during the preceding three months totaling several hundred thousand shares.